No Data
No Data
Pfizer to Advance Development of Modified-Release Formulation of Danuglipron
Pfizer (PFE) said Thursday it will conduct dose optimization studies of danuglipron in the second half of the year after selecting a once-daily, modified-release formulation of the drug candidate
Morgan Stanley Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $29
Morgan Stanley analyst Terence Flynn maintains $Pfizer(PFE.US)$ with a hold rating, and maintains the target price at $29.According to TipRanks data, the analyst has a success rate of 64.8% and a
Truist Financial Keeps Their Buy Rating on Pfizer (PFE)
Pfizer's Danuglipron Progress Met With Cautious Optimism Amidst Competitive Landscape
Hold Rating on Pfizer: Caution Advised Amid Uncertainties Surrounding Danuglipron
Analysts Offer Insights on Healthcare Companies: Demant (OtherWILLF) and Pfizer (PFE)
loading...